Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide vs Sitagliptin on Postprandial Glucose in T2DM
NCT00477581Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- May 2007
- Primary completion
- Sep 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Effect of Exenatide on postprandial glucose at 28 days. Started May 2007; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00477581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00477581.